Eisai Wins U.S. Drug Regulator Approval for Epilepsy Treatment

By Kartik Goyal

Nov. 15 (Bloomberg) -- The U.S. unit of Eisai Co., the maker of world's best-selling drug for Alzheimer's disease, has won the approval of the U.S. Food and Drug Administration to sell its Banzel drug for the treatment of epilepsy.

The drug, Banzel, an adjunctive treatment for partial-onset seizures in adults and adolescents of 12 years of age and older will be marketed in January 2009, the company said in a PRNnewswire statement.

To contact the reporter on this story: Kartik Goyal in New Delhi at kgoyal@bloomberg.net.